← Leaderboards
Michael O'Donnell
Beth Israel Deaconess Medical Center
$0
Attributed
$0
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
NIH$0 · 2
By mechanism
M01$0 · 2
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Michael B Atkins$4,622,469
- Mary Albrecht$387,832
- David Ives$387,832
- Bruce J Dezube$965,277
- Richard P Junghans$3,490,049
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchBladder NeoplasmDrug Screening /EvaluationNeoplasm /Cancer ImmunotherapyHuman SubjectHuman Therapy EvaluationIntravenous AdministrationNeoplasm /Cancer Relapse /RecurrenceBacillus Calmette Guerin VaccineRecombinant ProteinsClinical Trial Phase ICombination ChemotherapyDosageInterferon AlphaInterleukin 12
Grant awards (10)
INTERFERON ALPHA PLUS BCG VS BCG FOR TREATMENT OF AGGRESSIVE BLADDER CANCER$0
M01 · FY2002 · RR
INTRAVASCULAR ADMINISTRATION OF RH IL 12 IN CELL CARCINOMA OF THE BLADDER$0
M01 · FY2002 · RR
INTERFERON ALPHA PLUS BCG VS BCG FOR TREATMENT OF AGGRESSIVE BLADDER CANCER$0
M01 · FY2001 · RR
INTRAVASCULAR ADMINISTRATION OF RH IL 12 IN CELL CARCINOMA OF THE BLADDER$0
M01 · FY2001 · RR
INTRAVASCULAR ADMINISTRATION OF RH IL 12 IN CELL CARCINOMA OF THE BLADDER$0
M01 · FY2000 · RR
INTERFERON ALPHA PLUS BCG VS BCG FOR TREATMENT OF AGGRESSIVE BLADDER CANCER$0
M01 · FY2000 · RR
INTRAVASCULAR ADMINISTRATION OF RH IL 12 IN CELL CARCINOMA OF THE BLADDER$0
M01 · FY2000 · RR
INTERFERON ALPHA PLUS BCG VS BCG FOR TREATMENT OF AGGRESSIVE BLADDER CANCER$0
M01 · FY2000 · RR
INTERFERON ALPHA PLUS BCG VS BCG FOR TREATMENT OF AGGRESSIVE BLADDER CANCER$0
M01 · FY2000 · RR
INTRAVASCULAR ADMINISTRATION OF RH IL 12 IN CELL CARCINOMA OF THE BLADDER$0
M01 · FY2000 · RR